KR900007837A - 퀴누클리딘, 약제로서 이의 용도 및 이의 제조방법 - Google Patents
퀴누클리딘, 약제로서 이의 용도 및 이의 제조방법 Download PDFInfo
- Publication number
- KR900007837A KR900007837A KR1019890016802A KR890016802A KR900007837A KR 900007837 A KR900007837 A KR 900007837A KR 1019890016802 A KR1019890016802 A KR 1019890016802A KR 890016802 A KR890016802 A KR 890016802A KR 900007837 A KR900007837 A KR 900007837A
- Authority
- KR
- South Korea
- Prior art keywords
- carbon atoms
- formula
- compound
- acid addition
- group
- Prior art date
Links
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 title claims 3
- 239000003814 drug Substances 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 229910052717 sulfur Chemical group 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- MZMPQSXWRHYXCO-UHFFFAOYSA-N 3-(2-methylsulfanylethyl)-1-azabicyclo[2.2.2]octane Chemical compound C1CC2C(CCSC)CN1CC2 MZMPQSXWRHYXCO-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 235000020650 eye health related herbal supplements Nutrition 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (6)
- 하기 일반식(Ⅰ)의 퀴누클린딘 및 모든 라세미체, 에난티오머, 부분입체이성체 및 이의 혼합물, 및 이의 약리학적으로 허용되는 산 부가염, 및 3-메톡시-, 3-에톡시-, 3-알릴옥시-, 4-메틸티오-, 3-메톡시에틸- 및 3-메틸티오에틸-1-아자비사이클로[2,2,2]옥탄을 제외한 4급 염.상기식에서, R은 탄소원자수 1 내지 6의 알킬라디칼, 탄소원자수 3 내지 6의 알케닐 또는 탄소원자수 3 내지 6의 알키닐 라디칼이고, X는 산소 또는 황이며, n은 0,1 또는 2이다.
- 제1항에 있어서, X가 산소이고, n은 0 또는 1이며, R은 탄소원자수 1 내지 3의 알킬 그룹, 탄소원자수 3 또는 4의 알케닐 그룹 또는 탄소원자수 3 또는 4의 알키닐 그룹인 일반식(Ⅰ)의 퀴누클리딘, 및 모든 라세미체, 에난티오머, 부분입체이성체 및 이의 혼합물, 및 이의 약리학적으로 허용되는 산 부가염 및 이의 4급 염.
- R이 탄소원자수 1 내지 7의 알킬 라디칼, 탄소원자수 3 내지 6의 알케닐 라디칼 또는 탄소원자수 3 내지 6의 알키닐 라디칼이고, X가 산소 또는 황이며, n이 0,1 또는 2인 제1항에 따른 일반식(Ⅰ)의 퀴누클리딘 및 모든 라세미체, 에난티오머, 부분입체 이성체 및 이의 혼합물, 및 이의 약리학적으로 허용되는 산 부가염 및 이의 4급 염의 약제로서의 용도.
- 제1 또는 3항에 따른 일반식(Ⅰ)의 화합물 및 통상적인 보조제 및/또는 부형제를 함유하는 약제학적 제형.
- 일반식(Ⅰ)의 화합물을 통상적인 생약용 보조제 및/또는 부형제와 혼합함을 특징으로 하는 제4항에 따른 약제학적 제형의 제조방법.
- 하기 일반식(Ⅱ)의 화합물을 탈양자화시키고 일반식 Y-R(여기서, R은 제1항에서 정의한 바와 같고 Y는 이탈 그룹이다)의 알킬화제와 반응시킨 후, 보호 그룹을 제거하고, 경우에 따라 화합물을 산부가염 또는 이의 4급염으로 전환시키고/시키거나 경우에 따라 화합물을 이의 광학적으로 활성인 화합물로 분할시킴을 특징으로 하는 제1 또는 3항에 따른 일반식(Ⅰ)의 화합물의 제조방법.상기 식에서, n 및 X는 제1항에서 정의한 바와 같고, z는 보호그룹이며, X가 S인 경우 Z는 생략될 수 있다.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3839385A DE3839385A1 (de) | 1988-11-22 | 1988-11-22 | Neue quinuclidine, ihre herstellung als arzneimittel und verfahren zu ihrer herstellung |
DEP3839385.9 | 1988-11-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR900007837A true KR900007837A (ko) | 1990-06-02 |
KR0165667B1 KR0165667B1 (ko) | 1999-01-15 |
Family
ID=6367625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019890016802A KR0165667B1 (ko) | 1988-11-22 | 1989-11-20 | 퀴누클리딘, 약제로서의 이의 용도 및 이의 제조방법 |
Country Status (18)
Country | Link |
---|---|
US (2) | US5451587A (ko) |
EP (1) | EP0370415B1 (ko) |
JP (1) | JPH0686449B2 (ko) |
KR (1) | KR0165667B1 (ko) |
AU (1) | AU628884B2 (ko) |
BG (1) | BG61859B2 (ko) |
CA (1) | CA2003422C (ko) |
DE (3) | DE8817121U1 (ko) |
DK (1) | DK170167B1 (ko) |
ES (1) | ES2054988T3 (ko) |
FI (1) | FI91637C (ko) |
HU (1) | HU202527B (ko) |
IE (1) | IE62328B1 (ko) |
IL (1) | IL92377A (ko) |
NO (1) | NO172801C (ko) |
NZ (1) | NZ231445A (ko) |
PT (1) | PT92368B (ko) |
ZA (1) | ZA898858B (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030083289A (ko) * | 2002-04-20 | 2003-10-30 | 한승호 | 다공질 화분 |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1307790C (en) * | 1987-08-04 | 1992-09-22 | Ian Anthony Cliffe | Ethers |
YU84791A (sh) * | 1990-05-19 | 1994-06-10 | Boehringer Ingelheim Kg. | Biciklicni 1-aza-cikloalkalni |
EP0492903A1 (en) * | 1990-12-21 | 1992-07-01 | MERCK SHARP & DOHME LTD. | Substituted pyrazines, pyrimidines and pyridazines for use in the treatment of glaucoma |
EP0492902A1 (en) * | 1990-12-21 | 1992-07-01 | MERCK SHARP & DOHME LTD. | Substituted pyridine derivatives for use in the treatment of glaucoma |
EP0492904A1 (en) * | 1990-12-21 | 1992-07-01 | MERCK SHARP & DOHME LTD. | Substituted benzene derivatives for use in the treatment of glaucoma |
ZA92278B (en) * | 1991-02-01 | 1992-10-28 | Akzo Nv | 3-quinuclidine derivatives |
GB9122988D0 (en) * | 1991-10-30 | 1991-12-18 | Ici Plc | Heterocyclic compounds |
GB9127279D0 (en) * | 1991-12-23 | 1992-02-19 | Ici Plc | Heterocyclic derivatives |
WO1993021184A1 (en) * | 1992-04-10 | 1993-10-28 | Zeneca Limited | Biphenylylquinuclidine derivatives as squalene synthase inhibitors |
GB9211796D0 (en) * | 1992-06-04 | 1992-07-15 | Ici Plc | Heterocyclic derivatives |
GB9216721D0 (en) * | 1992-08-06 | 1992-09-23 | Ici Plc | Therapeutic heterocyclic derivatives |
GB9218334D0 (en) * | 1992-08-28 | 1992-10-14 | Ici Plc | Heterocyclic compounds |
DE4236331A1 (de) * | 1992-10-28 | 1994-05-05 | Boehringer Ingelheim Kg | Synergistische Kombination |
GB9226573D0 (en) * | 1992-12-21 | 1993-02-17 | Ici Plc | Heterocyclic compounds |
US5998404A (en) | 1994-10-24 | 1999-12-07 | Eli Lilly And Company | Heterocyclic compounds and their use |
US5512574A (en) * | 1994-12-21 | 1996-04-30 | American Home Products Corporation | Quinuclidine and azabicyclo 2.2.1! heptane pyrazinyl ethers as muscarinic agonists |
ES2147889T3 (es) * | 1996-01-19 | 2000-10-01 | Lonza Ag | Metodo para preparar 3-hidroxiquinuclidinol opticamente activo. |
SE9600683D0 (sv) * | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
CZ54498A3 (cs) * | 1997-03-07 | 1998-11-11 | Lonza Ag | Katalyzátorová směs na bázi amorfního částečně dehydratovaného hydroxidu zirkoničitého a způsob její výroby a použití |
AU6896098A (en) * | 1997-04-11 | 1998-11-11 | Eli Lilly And Company | Method for treating schizophrenia |
US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
DE10106971A1 (de) * | 2001-02-15 | 2002-08-29 | Boehringer Ingelheim Pharma | Arzneimittelformulierung die einen muskarinischen Agonisten enthält |
KR100448002B1 (ko) * | 2002-02-01 | 2004-09-13 | 한국과학기술연구원 | 신규한 퀴누클리딘 화합물 및 그 제조방법 |
GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
PE20060437A1 (es) | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
US7678363B2 (en) * | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
MX2008014320A (es) | 2006-05-09 | 2009-03-25 | Braincells Inc | Neurogenesis mediada por el receptor de 5-hidroxitriptamina. |
EP2068872A1 (en) | 2006-09-08 | 2009-06-17 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2014831A1 (en) * | 1968-08-01 | 1970-04-24 | Sogeras | Quinuclidinyl and quinuclidinylalkyl ethers with cholino - lytic, antihistaminic and neurosedative activity |
IE63906B1 (en) * | 1987-11-13 | 1995-06-14 | Novo Nordisk As | Azabicyclic compounds and their preparation and use |
-
1988
- 1988-11-22 DE DE8817121U patent/DE8817121U1/de not_active Expired - Lifetime
- 1988-11-22 DE DE3839385A patent/DE3839385A1/de not_active Withdrawn
-
1989
- 1989-11-18 ES ES89121387T patent/ES2054988T3/es not_active Expired - Lifetime
- 1989-11-18 EP EP89121387A patent/EP0370415B1/de not_active Expired - Lifetime
- 1989-11-18 DE DE8989121387T patent/DE58904567D1/de not_active Expired - Lifetime
- 1989-11-20 KR KR1019890016802A patent/KR0165667B1/ko not_active IP Right Cessation
- 1989-11-20 NZ NZ231445A patent/NZ231445A/xx unknown
- 1989-11-21 IL IL9237789A patent/IL92377A/en not_active IP Right Cessation
- 1989-11-21 FI FI895531A patent/FI91637C/fi active IP Right Grant
- 1989-11-21 CA CA002003422A patent/CA2003422C/en not_active Expired - Lifetime
- 1989-11-21 HU HU896032A patent/HU202527B/hu unknown
- 1989-11-21 NO NO894630A patent/NO172801C/no not_active IP Right Cessation
- 1989-11-21 ZA ZA898858A patent/ZA898858B/xx unknown
- 1989-11-21 PT PT92368A patent/PT92368B/pt not_active IP Right Cessation
- 1989-11-21 IE IE371289A patent/IE62328B1/en not_active IP Right Cessation
- 1989-11-21 JP JP1303037A patent/JPH0686449B2/ja not_active Expired - Lifetime
- 1989-11-21 DK DK584089A patent/DK170167B1/da not_active IP Right Cessation
- 1989-11-22 AU AU45403/89A patent/AU628884B2/en not_active Expired
-
1994
- 1994-02-18 BG BG98490A patent/BG61859B2/bg unknown
- 1994-05-12 US US08/241,517 patent/US5451587A/en not_active Expired - Lifetime
-
1995
- 1995-06-16 US US08/491,463 patent/US5508405A/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030083289A (ko) * | 2002-04-20 | 2003-10-30 | 한승호 | 다공질 화분 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR900007837A (ko) | 퀴누클리딘, 약제로서 이의 용도 및 이의 제조방법 | |
DZ1067A1 (fr) | Nouvelles préparations pharmaceutiques à emission prolongée. | |
KR860007207A (ko) | 페닐 카르바메이트 및 이것의 염을 제조하는 방법 | |
GR1001503B (el) | Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών. | |
NL950022I2 (nl) | Analoga van mevalolacton en derivaten daarvan, werkwijzen voor hun bereiding, farmaceutische prepar aten die ze bevatten en hun toepassing als farmaceutica. | |
ATE66609T1 (de) | Loesungen von oxazaphosphorinen mit verbesserter stabilitaet und verfahren zu deren herstellung. | |
KR900018027A (ko) | 피페리딘 유도체, 그의 제조 방법, 및 그것을 유효성분으로 함유하는 의약용 조성물 | |
DE3773017D1 (de) | Nicorandil enthaltende zubereitung zum einspritzen. | |
IE43278L (en) | Diphenyl sulfides. | |
PT84680B (pt) | Processo para a preparacao de derivados de 1,5-benzotiazepina e de composicoes farmaceuticas que os contem | |
KR880004810A (ko) | 소화성 궤양 치료제 | |
ATE1442T1 (de) | Pharmazeutisches mittel, enthaltend all-e- oder 13-z-7,8-dehydro-retinsaeure und verfahren zu seiner herstellung. | |
KR870008834A (ko) | 아실-보효소 a:클레스테롤 아실 전이 효소의 억제제로서의 올레인산, 리놀산 또는 리놀렌산의 치환 아닐리드 | |
KR890012960A (ko) | 결정성 β-락탐 용매화물 | |
ATE16564T1 (de) | Arzneimittelloesungen und verfahren zu deren herstellung. | |
KR940021524A (ko) | 1,2,5,6-테트라하이드로피리딘 유도체와 이의 제조 방법 및 치료시 이의 이용방법 | |
DK19885D0 (da) | 3-alkoxy-2-(n-pyrrolidino)-n-pyridyl-n-furyl (eller thienyl)-methyl-propylaminer, fremgangsmaade til fremstilling deraf, samt farmaceutiske midler indeholdende disse | |
KR910011258A (ko) | 녹내장의 치료방법 | |
KR900004713A (ko) | 디아민 유도체 및 그의 제조방법 | |
KR870001153A (ko) | 디페녹시에틸아민 유도체가 함유된 약제조성물 및 그의 생산방법 | |
KR890003678A (ko) | 부정맥 치료제 | |
SE8303719L (sv) | Eburnan-oximderivat, forfarande for framstellning derav samt farmaceutiska kompositioner innehallande dessa foreningar | |
KR890001582A (ko) | 향류머티스제 | |
ATE82289T1 (de) | 1-hydroxyalkylxanthine, verfahren zu ihrer herstellung und sie enthaltende medikamente. | |
ES481936A2 (es) | Mejoras introducidas en la patente principal: procedimiento para la obtencion de compuestos oxotio. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120910 Year of fee payment: 15 |
|
EXPY | Expiration of term |